Streptococcus equi vaccine (recombinant proteins)

This medicine is authorised for use in the European Union.


Strangvac is a veterinary vaccine given to horses from 8 months of age to reduce clinical signs of the acute stage of strangles. Strangles is an infection of the upper respiratory tract and regional lymph nodes of horses caused by the bacterium Streptococcus equi.

Strangvac contains Streptococcus equi proteins CCE, Eq85 and IdeE. The vaccine is intended for use in horses in areas where Streptococcus equi is known to be present and who are at high risk of infection.


This EPAR was last updated on 27/10/2021

Authorisation details

Product details
Agency product number
Active substance
  • Recombinant Streptococcus equi protein CCE
  • Recombinant Streptococcus equi protein Eq85
  • Recombinant Streptococcus equi protein IdeE
International non-proprietary name (INN) or common name
Streptococcus equi vaccine (recombinant proteins)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Intervacc AB
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Vastertorpsvagen 135
SE-129 44 Hagersten

Product information

Strangvac - EMEA/V/C/005309 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for equidae

Therapeutic indication

For the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with S. equi.

Assessment history

Related content

How useful was this page?

Add your rating
5 ratings